Home
Sanaria

Sanaria Market Share Analysis for November 2025

Sanaria is a biotechnology company developing vaccines protective against malaria and other infectious diseases as well as related products for use in malaria research.

Health > Biotechnology and Pharmaceuticals

Domainsanaria.com

Year Founded2003

Employees51 - 200

Annual Revenue$50M - $75M

Sanaria

Sanaria (including company regionals)

sanaria.com

See more website traffic and engagement information

Sanaria Revenue up to November 2025 is 50M - 75M

revenue generated by Sanaria top domains

Sanaria top domains revenue over 3 years

Revenue for Sanaria top domains

sanaria.com50M - 75M

See more with Sales Intelligence

Total visits to Sanaria's top domains

Understand Sanaria market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

sanaria.com1.2K

See more with Sales Intelligence

Avg. visit duration in Sanaria's top domains

Analyze Sanaria engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

sanaria.com00:00:43

See more with Sales Intelligence

Avg. pageviews on Sanaria's top domains

See how Sanaria keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

sanaria.com1.53

See more with Sales Intelligence

Sanaria top competitors by domain

Top similar sites in November 2025, ranked by their affinity

biocentury.comCompany NameBioCenturyEmployees51 - 200HQUnited States, California, Redwood CityAnnual revenue$15M - $25MTotal visits74.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Sanaria

These are the website technologies, by industry, used by Sanaria top domains

Widget (5)

Twemoji

Content Management System (3)

WordPress

Social (3)

Facebook Connect

Advertising (2)

Google Adsense

More Technologies

7

See all

News & Signals from Sanaria

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSanaria Inc. launched PfSPZ-LARC2 trials in the U.S. and Germany on Jan 1st '25.This year, Sanaria plans to launch additional PfSPZ-LARC2 trials in the U.S. and Germany as the company targets a global rollout within three years.

NewsSanaria Inc. has issues with controlled human malaria infections.Sanaria(R) has pioneered production of aseptic, purified, vialed cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) as vaccines and for controlled human malaria infections.

NewsSanaria Inc. received award Best Logistics Technology and Cold Chain Delivery Award at Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress on Apr 2nd '24.Sanaria wins Best Logistics Technology and Cold Chain Delivery Award.